Bromocryptine-cyclofenil associated therapy: an effective and safe mode of treatment of female normoprolactinemic infertility.

In 51 infertile normoprolactinemic women, aged 19 to 44 years, with anovulatory menstrual cycles and with no endocrine disorders, who had never conceived after the currently employed drugs for female sterility (human chorionic gonadotropin, human menopausal gonadotropin, clomiphene, cyclofenil, bromocryptine itself) a new therapeutic approach was tried: cyclofenil and bromocryptine in association. Before the treatment, a standard luteinizing hormone (LH)-releasing hormone (LHRH) test (100 micrograms intravenously) was performed for each woman to evaluate serum gonadotropin and prolactin response; furthermore, the urinary estrogen excretion or the serum 17-beta-estradiol concentration had been evaluated in all women. The schedule of treatment was as follows: cyclofenil, 600 mg/day, from the 5th to the 12th day of the cycle and bromocryptine, 2.5 mg/day, from the 5th to the 26th day. This scheme was employed for three successive trials at the most. Forty pregnancies (80%) were achieved with the associated therapy, almost all (37) within the second treatment cycle. Thirty-one women delivered a vital baby, five are now pregnant, four aborted spontaneously. All seven women who had been unsuccessfully treated with bromocryptine alone, conceived after the associated regimen. In view of the excellent therapeutic results achieved in our hands, it is justified to consider our proposed scheme cyclofenil-bromocryptine an effective therapy for the management of infertile normo-prolactinemic women.